Alkermes plc (NASDAQ:ALKS) Q4 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Alkermes Fourth Quarter 2024 Financial Results Conference Call. My name is Melissa, and I will be your operator for today's call.
Alkermes Plc. (ALKS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 5,478,728 | $157,568,217 | +2% | 0.23% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 4,181,751 | $120,267,159 | 1.28% | |
| 3. | VenBio Select Advisor Kurt Von Emster | 2,450,000 | $70,462,000 | 0.99% | |
| 4. | Commodore Capital Egen Atkinson And Michael Kramarz | 2,300,000 | $66,148,000 | -21% | 4.84% |
| 5. | AQR Capital Management Cliff Asness | 811,541 | $23,339,919 | -3% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.31 | 35,000 | Director | 80,000 | 2022-11-14 | Filing | |
| $23.43 | 427 | Director | 9,366 | 2022-03-04 | Filing | |
| $30.22 | 1,650 | Director | 1,650 | 2021-08-23 | Filing | |
| $26.43 | 10,000 | Director | 10,000 | 2021-08-02 | Filing | |
| $19.65 | 6,940 | Director | 11,242 | 2020-02-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $35.69 | 1,327 | Officer | 7,717 | 2025-02-20 | Filing | |
| $36.02 | 108,833 | Officer | 57,875 | 2025-02-13 | Filing | |
| $34.02 | 35,586 | Officer | 166,708 | 2025-02-13 | Filing | |
| $33.27 | 33,108 | Officer | 57,875 | 2025-02-12 | Filing | |
| $32.69 | 171,813 | Officer | 90,983 | 2025-02-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 27,852,909 | $801,049,664 | 0.01% | |
| 2. | 18,496,185 | $531,950,280 | 0% | |
| 3. | 8,814,975 | $253,518,681 | 0.01% | |
| 4. | 7,557,835 | $217,363,335 | 3.28% | |
| 5. | 7,012,483 | $201,679,011 | 0.03% |
News See All
Alkermes plc (NASDAQ:ALKS) Q3 2024 Earnings Call Transcript
Operator: Greetings and welcome to the Alkermes' Third Quarter 2024 Financial Results Conference Call. My name is Maria and I'll be your operator for today's call.
10 Most Undervalued Quality Stocks To Buy According To Analysts
Despite global uncertainties, the US economy is viewed as stronger than its international counterparts.
Alkermes plc (NASDAQ:ALKS) Q2 2024 Earnings Call Transcript
Operator: Greetings and welcome to the Alkermes' Second Quarter 2024 Financial Results Conference Call. My name is Rob and I'll be your operator for today's call.
Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call Transcript
Alkermes plc misses on earnings expectations. Reported EPS is $0.22 EPS, expectations were $0.46.
5 Most Promising Psychedelic Stocks According to Hedge Funds
In this piece, we will take a look at the five most promising psychedelic stocks according to hedge funds.
12 Best Growth Stocks to Buy According to Billionaire Ray Dalio's Bridgewater Associates
In this piece, we will take a look at the 12 best growth stocks to buy according to billionaire Ray Dalio's Bridgewater Associates.
Jim Simons Stock Portfolio: 12 Biggest Healthcare Stocks
In this piece, we will take a look at the 12 biggest healthcare stocks in Jim Simons' stock portfolio.
5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
Below we present the list of 5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds.
Alkermes plc (NASDAQ:ALKS) Q3 2023 Earnings Call Transcript
Operator: Greetings. And welcome to the Alkermes Third Quarter 2023 Financial Results Conference Call. My name is Donna and I’ll be your operator for today’s call.
Billionaire Hedge Funds
